The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ABBVIE INC | COM | 00287Y109 | 649 | 6,000 | SH | SOLE | 6,000 | 0 | 0 | ||
| ARCUS BIOSCIENCES INC | COM | 03969F109 | 281 | 10,000 | SH | SOLE | 10,000 | 0 | 0 | ||
| ARDELYX INC | COM | 039697107 | 331 | 50,000 | SH | SOLE | 50,000 | 0 | 0 | ||
| ATRECA INC | CL A COM | 04965G109 | 276 | 18,000 | SH | SOLE | 18,000 | 0 | 0 | ||
| BIOMARIN PHARMACEUTICAL INC | COM | 09061G101 | 755 | 10,000 | SH | SOLE | 10,000 | 0 | 0 | ||
| FATE THERAPEUTICS INC | COM | 31189P102 | 660 | 8,000 | SH | SOLE | 8,000 | 0 | 0 | ||
| GRITSTONE ONCOLOGY INC | COM | 39868T105 | 349 | 37,000 | SH | SOLE | 37,000 | 0 | 0 | ||
| ORCHARD THERAPEUTICS PLC | ADS | 68570P101 | 109 | 15,000 | SH | SOLE | 15,000 | 0 | 0 | ||
| REGENERON PHARMACEUTICALS | COM | 75886F107 | 710 | 1,500 | SH | SOLE | 1,500 | 0 | 0 | ||
| REVOLUTION MEDICINES INC | COM | 76155X100 | 459 | 10,000 | SH | SOLE | 10,000 | 0 | 0 | ||
| ROCKET PHARMACEUTICALS INC | COM | 77313F106 | 355 | 8,000 | SH | SOLE | 8,000 | 0 | 0 | ||
| TELADOC HEALTH INC | COM | 87918A105 | 273 | 1,500 | SH | SOLE | 1,500 | 0 | 0 | ||
| TG THERAPEUTICS INC | COM | 88322Q108 | 337 | 7,000 | SH | SOLE | 7,000 | 0 | 0 | ||
| VERTEX PHARMACEUTICALS INC | COM | 92532F100 | 645 | 3,000 | SH | SOLE | 3,000 | 0 | 0 | ||